Medicare beneficiaries waiting on drug approvals from their Part D plans could soon face a hard deadline of 72 hours for standard prior-authorization decisions, with 24 hours for expedited requests. The Centers for Medicare and Medicaid Services (CMS) published a proposed rule, CMS-0062-P, on April 14, 2026, and the public comment window closes June 15, 2026. That leaves nine days for plans, providers, patient advocates, and technology vendors to weigh in on a change that would reshape how quickly enrollees learn whether their prescriptions are covered.
Why the 72-hour clock changes the calculus for Part D sponsors
The proposed rule would require Part D sponsors to notify the enrollee and prescriber of a coverage determination no later than 72 hours after receiving a standard prior-authorization request for a Part D drug, as detailed in the Federal Register notice. Expedited requests would carry a tighter window: plans would need to respond within 24 hours, consistent with CMS’s existing coverage-determination framework. For beneficiaries, the practical effect is straightforward. A patient whose doctor prescribes a specialty medication would know within three days whether the plan will cover it, instead of waiting through an open-ended review that can delay treatment or force out-of-pocket spending.
CMS is not writing on a blank slate. In February 2024, the agency finalized CMS-0057-F, which established prior-authorization decision timeframes of 72 hours for expedited requests and seven calendar days for standard requests for non-drug items and services such as imaging, procedures, and durable medical equipment. The new proposal would extend comparable speed requirements to prescription drugs, closing a timing gap that left Part D medications under looser expectations even as medical services moved to fixed deadlines.
For Part D sponsors, the timing requirement interacts directly with technology choices. Plans that already adopted HL7 FHIR-based APIs and Da Vinci implementation guides to comply with the 2024 non-drug rule have a head start: their systems can capture structured prior-authorization data, route it to utilization management staff, and return decisions electronically. Sponsors still relying primarily on legacy NCPDP e-prescribing transactions, referenced in 42 CFR 423.160, face a steeper technical lift to meet the proposed drug-specific standard, because those workflows were not designed around real-time interoperability or tight response clocks.
CMS’s technical expectations are explicit. In its interoperability materials, the agency points to FHIR APIs, NCPDP standards, and Da Vinci implementation guides as the backbone for modern prior-authorization exchanges. That signals a policy preference for interoperable, API-driven authorization instead of fax-and-phone cycles that can stretch over days. For plans, complying with a 72-hour outer limit will likely require automation to triage routine cases, standardized clinical documentation requests, and tighter integration with electronic health records and pharmacy systems.
What CMS-0062-P and related guidance actually establish
The proposed rule spans pages 19890 through 20062 in the Federal Register as FR Doc. 2026-07205. CMS frames the policy as a way to speed patient access to drugs, increase transparency, and reduce administrative burden across Medicare Advantage, Medicaid, and Part D. In a separate announcement, the agency described the package as major reforms intended to accelerate access to therapies and curb paperwork, emphasizing that prior authorization should be a tool for appropriate care rather than a barrier. According to a CMS press release, the proposal ties faster decision-making to clearer data-sharing rules so that providers know what documentation is needed and patients can see how coverage decisions are made.
CMS also released a technical summary outlining how the drug-related provisions build on the interoperability architecture created for non-drug services. That document explains that payers would be expected to expose APIs to support prior-authorization requests, responses, and status checks for prescription drugs, aligning drug workflows with the standards already being adopted for medical benefits. The agency’s fact sheet underscores that the same core data standards and implementation guides would apply, creating a more uniform experience for clinicians who order both drugs and services for their patients.
For providers, a uniform 72-hour standard for drug decisions offers more predictable planning. Clinicians could schedule follow-up visits or lab monitoring with greater confidence that a prescribed medication will either be approved promptly or that an alternative will be needed. For pharmacies, shorter and more reliable turnaround could reduce abandoned prescriptions and repeated outreach to prescribers when coverage is uncertain.
Beneficiaries stand to gain from both the timing limits and the transparency provisions. Faster decisions can reduce gaps in therapy when patients transition between plans or move from hospital to home, moments when delays can be clinically risky. At the same time, standardized electronic communication can make it easier for patients and caregivers to understand why a drug was denied and what options-such as exceptions, appeals, or therapeutic alternatives-are available.
Part D sponsors, however, will need to balance compliance with operational realities. Meeting a 72-hour clock for all standard drug prior authorizations could require additional staffing, upgraded utilization management platforms, and closer coordination with pharmacy benefit managers. Plans that invest early in interoperable APIs and automation may find that the same tools that support regulatory compliance also reduce manual work and call volumes over time.
As the June 15, 2026, comment deadline approaches, stakeholders are likely to focus on whether the proposed timeframes are feasible, how they interact with existing state laws, and what flexibilities plans might need for complex cases. CMS has signaled that it views timely, electronic prior authorization as central to patient-centered coverage, and the final rule will determine how quickly that vision reshapes the Part D experience.
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
